Tags : cemiplimab

Regeneron Collaborates with BioNTech to Advance the Combination of FixVac

Tuba Khan August 3, 2020

Shots: The two companies collaborated to jointly conduct P-II study combining BNT111 FixVac and Libtayo in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma with the expected initiation of the study in Q4’20 The companies will equally share the development costs for the clinical trial and will contribute their products for the trial. […]Read More

Biotech Clinical Trials

Sanofi and Regeneron Report Results of Libtayo (cemiplimab) in a

Tuba Khan May 6, 2020

Shots: Shots: The ongoing P-II study involves assessing Libtayo (300mg, IV, q3w) for up to 93 wks. or until disease progression, unacceptable toxicity, withdrawal of consent or confirmed complete response in 132 patients with advanced BCC who were intolerant to prior HHI therapy The P-II study results: ORR (29% in patients with LA disease) with […]Read More

Biotech Regulatory

Regeneron and Sanofi’s Libtayo (cemiplimab) Receives European Commission’s Approval for

Tuba Khan July 2, 2019

Shots: The conditional marketing authorization is based on the results from P-II EMPOWER-CSCC-1 (Study 1540) and supported by two advanced CSCC expansion cohorts from P-I study evaluating a Libtayo in patients with advanced CSCC The conditional approval is to meet unmet needs in advance CSCC, and the companies will generate additional data supporting the benefit-risk […]Read More

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar, aflibercept) in Korea

Biocon Biologics and Viatris Receive CHMP’s Positive Opinion for Abevmy (biosimilar, bevacizumab)

Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Regeneron’s Ab Cocktail (casirivimab + imdevimab) Receives the CHMP’s Positive Opinion to Treat COVID-19

Kite’s Yescarta Receives the US FDA’s Approval for R/R Follicular Lymphoma

Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US

Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI

Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve Adults at CROI 2021

Tags : cemiplimab

Regeneron Collaborates with BioNTech to Advance the Combination of FixVac

Sanofi and Regeneron Report Results of Libtayo (cemiplimab) in a

Regeneron and Sanofi’s Libtayo (cemiplimab) Receives European Commission’s Approval for

Latest Posts

Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar, aflibercept) in Korea

ViewPoints Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10)

Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI

Kite’s Yescarta Receives the US FDA’s Approval for R/R Follicular Lymphoma

Tags : cemiplimab

Latest Posts

Categories

Related Topics